Skip to content
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.
Company
Companies

Carna Biosciences

カルナバイオサイエンス

4572 · TSE · Pharmaceutical · 1 article

Financials Consolidated

Revenue¥579m−9.0% year on yearConsolidated · FY12/25

Ordinary profit−¥2.14bnConsolidated · FY12/25

Net profit−¥2.17bnConsolidated · FY12/25

Performance over time

Revenue
¥2.02bnFY12/21
¥1.39bnFY12/22
¥1.63bnFY12/23
¥636mFY12/24
¥579mFY12/25
Ordinary profit
−¥523mFY12/21
−¥1.28bnFY12/22
−¥1.13bnFY12/23
−¥2.08bnFY12/24
−¥2.14bnFY12/25
Net profit (attributable)
−¥534mFY12/21
−¥1.35bnFY12/22
−¥1.15bnFY12/23
−¥2.18bnFY12/24
−¥2.17bnFY12/25
Op. cash flow
−¥1.54bnFY12/21
−¥708mFY12/22
−¥1.68bnFY12/23
−¥1.37bnFY12/24
−¥2.16bnFY12/25

People & pay

Employees, whole group61 peopleFY12/25

Employees, parent company (non-consolidated)57 peopleFY12/25

Average salary¥7.92mFY12/25

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history
Five-year history
Fiscal yearRevenueOrdinary profitNet profit (attributable)EPSTotal assetsNet assetsOp. cash flow
FY12/25¥579m−9.0% year on year−¥2,145m−¥2,171m−¥113.62¥1.23bn¥309m−¥2,159m
FY12/24¥636m−60.9% year on year−¥2,081m−¥2,179m−¥121.64¥2.77bn¥2,475m−¥1,375m
FY12/23¥1,626m+17.2% year on year−¥1,126m−¥1,153m−¥68.62¥4.35bn¥3,878m−¥1,677m
FY12/22¥1,387m−31.3% year on year−¥1,279m−¥1,350m−¥99.10¥4.27bn¥3,642m−¥708m
FY12/21¥2,018m−¥523m−¥534m−¥42.10¥5.43bn¥4,316m−¥1,537m

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100XSFK · Japan GAAP. Each figure's years come from one report's five-year summary.

Latest coverage

TSE:4572

  1. Carna turns MD Anderson leukemia pact into a binding trial contract, and will pay for it

    Carna Biosciences will supply monzosertib and bear study costs in a Phase 1b trial at MD Anderson for relapsed or refractory AML, now under a signed contract; the notice reports no patient entry or results, and Carna will not routinely announce registry updates.

5% holders

Latest disclosed holders and exits below 5%.

2 holders · data through

5% holders
HolderStakeChangePurposeFiling
CANTOR FITZGERALD EUROPE25.99%+1.42 ppPure investmentPure investment
Original (Japanese)純投資
Filed  — filing S100ZD01
五味 大輔13.68%+7.02 ppPure investmentPure investment
Original (Japanese)純投資
Filed  — filing S100Z93Q

Cross-holdings

Strategic shareholdings and sales, by fiscal year.

1 fiscal year · data through

Balance-sheet value is the reporting company's own listed holdings (its largest holding subsidiary's where marked), carried at market value; the percentage divides it by consolidated net assets in the same annual report.

Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Dec 20251¥16.8m5.43%——Filed  — filing S100XSFK

Fund positioning

Current holdings disclosed by tracked funds.

1 fund · data through

Held by 1 tracked fund; largest weight 0.12%. Holdings as of 19 Nov 2026.

Fund positioning
FundNAV weight
TSE Growth 250 ETF0.12%